Slide 1: Exchange filing cover letter for Q2 FY25 Investor Presentation
12th November, 2024 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Street, For, “Exchange Plaza”, Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir / Madam, Sub: - Q2 FY25
Slide 2: NATCO Pharma Limited Earnings Presentation Q2 FY25
NATCO Pharma Limited Earnings Presentation Q2 FY25
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Q2FY25 – Key Business & Consolidated Financial Highlights
Q2FY25 – Key Business & Consolidated Financial Highlights Total Revenue stood at INR 14,349 mn| Pharma Export Formulations at INR 12,113 mn | Domestic Formulations Revenue at INR 1,023 mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 8,681 mn and EBITDA Margin at 60.5% for
Slide 5: Q2FY25 – Quarterly Performance
Q2FY25 – Quarterly Performance Revenue Breakup (INR mn) Revenue Breakup (%) – Q2FY25 1% 4%4% Revenue Division Q2FY25 Q2FY24 Q1FY25 7% API Revenue 496 778 392 Formulation Formulation – Exports (incl profit share, 84% license income, export service income & 12,113 7,923 12,101 Subsidiaries) Export For
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Mn) Q2FY25 Q2FY24 Q1FY25 Total Revenue 14,349 10,608 14,107 Total Expenses (before finance cost and depreciation) 5,668 5,734 5,578 Earnings before interest, tax, depreciation and amortization (EBITDA) 8,681 4,874 8,529 EBITDA Margin*
Slide 7: Key Product Pipeline - USA
Key Product Pipeline - USA 30 Para IVs in the pipeline 14 Approved (either tentative or fully) Key Sole FTFs (Para IV) in the pipeline Key Para IV (shared FTFs) products in the pipeline Therapeutic Therapeutic Key Brand Molecule Segment / Primary Key Brand Molecule Segment / Primary Indication Indic
Slide 8: Earnings Call Details – Q2FY25
Earnings Call Details – Q2FY25 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences are as below: Details of the Earnings ca
Slide 9: Thank You
Thank You Contact: Rajeev Menon – Investor Relations Rajesh Chebiyam – EVP, Crop Health Sciences r.menon@natcopharma.co.in / Rajesh.Chebiyam@natcopharma.co.in 040-23546208/ Ext: 323 https://twitter.com/pharma_natco https://www.linkedin.com/company/natcopharma